Home » Stocks » IDRA

Idera Pharmaceuticals, Inc. (IDRA)

Stock Price: $5.95 USD 0.01 (0.17%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
Market Cap 226.10M
Revenue (ttm) n/a
Net Income (ttm) -87.24M
Shares Out 35.09M
EPS (ttm) -2.72
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $5.95
Previous Close $5.94
Change ($) 0.01
Change (%) 0.17%
Day's Open 5.95
Day's Range 5.69 - 6.00
Day's Volume 548,417
52-Week Range 1.06 - 6.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

EXTON, Pa., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will provide a company outlook for 2021 at upcoming conferences.

Zacks Investment Research - 1 month ago

Idera Pharmaceuticals (IDRA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

GlobeNewsWire - 1 month ago

EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement ...

GlobeNewsWire - 2 months ago

– COO Role is Key to Preparedness for NDA Filing and Commercial Launch – – Clayton Fletcher , Head of Business Development & Strategic Planning , to Retire –

GlobeNewsWire - 2 months ago

ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances ILLUMINATE-301 Continues on Track and Beyond Melanoma Strategy Advances

GlobeNewsWire - 3 months ago

– Protects Method-of-Use in CRC and HNSCC – – Protects Method-of-Use in CRC and HNSCC –

GlobeNewsWire - 4 months ago

EXTON, Pa., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera”) (Nasdaq: IDRA) today announced that final data from the ILLUMINATE-204 trial investigating intratumoral t...

GlobeNewsWire - 5 months ago

Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track Enhanced Financial Flexibility as ILLUMINATE-301 Continues on Track

GlobeNewsWire - 6 months ago

EXTON, Pa., July 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with institutional investors provid...

GlobeNewsWire - 7 months ago

EXTON, Pa., June 02, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today announced preliminary data from the first 10 patients in the safety cohort of  I...

GlobeNewsWire - 9 months ago

– Overall response rate of 22% – – Disease control rate of 71% – – Median overall survival of 21 months – – Key topline data from ILLUMINATE-301 expected in Q1 2021 –

GlobeNewsWire - 9 months ago

EXTON, Pa., April 07, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced entering into an agreement with a fund affiliated with an institutional investor pro...

GlobeNewsWire - 10 months ago

– Completed Enrollment in ILLUMINATE-301; Top-Line Overall Response Rate (ORR) Data Expected in Q1 2021 – – Completed Enrollment in ILLUMINATE-301; Top-Line Overall Response Rate (ORR) Data Ex...

Zacks Investment Research - 10 months ago

Idera (IDRA) closes enrollment in the late-stage ILLUMINATE-301 study, evaluating the combo of tilsotolimod plus Yervoy in patients with anti-PD-1 refractory advanced melanoma.

GlobeNewsWire - 10 months ago

Overall Response Rate (ORR) Data Anticipated Q1 2021 Overall Response Rate (ORR) Data Anticipated Q1 2021

GlobeNewsWire - 1 year ago

EXTON, Pa., Dec. 23, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today it is entering into an agreement with funds affiliated with an insti...

GlobeNewsWire - 1 year ago

EXTON, Pa., Oct. 21, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), or the Company, announced today that the U.S. Patent and Trademark Office will issue on November 5, ...

GlobeNewsWire - 1 year ago

EXTON, Pa., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) announced today the initiation of a phase 2 trial, ILLUMINATE-206 which will evaluate tilsotolimod, ...

GlobeNewsWire - 1 year ago

EXTON, Pa., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that the company will present at the Baird 2019 Global Healthcare Conference on Wedne...

Seeking Alpha - 1 year ago

Idera Pharmaceuticals, Inc. (IDRA) CEO Vincent Milano on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

Idera (IDRA) delivered earnings and revenue surprises of 7.14% and 1348.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

As of late, it has definitely been a great time to be an investor in Idera Pharmaceuticals, Inc. (IDRA).

Zacks Investment Research - 1 year ago

Idera (IDRA) delivered earnings and revenue surprises of 13.04% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Idera (IDRA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About IDRA

Idera Pharmaceuticals, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for oncology and rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, metastatic melanoma, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has collaboration and supply agreement with AbbVie Inc. and Bristo... [Read more...]

Industry
Biotechnology
IPO Date
Jan 24, 1996
CEO
Vincent Milano
Employees
36
Stock Exchange
NASDAQ
Ticker Symbol
IDRA
Full Company Profile

Financial Performance

In 2019, IDRA's revenue was $1.45 million, an increase of 118.73% compared to the previous year's $662,000. Losses were -$56.52 million, -5.62% less than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for IDRA stock is "Buy." The 12-month stock price forecast is 7.83, which is an increase of 31.60% from the latest price.

Price Target
$7.83
(31.60% upside)
Analyst Consensus: Buy